首页> 美国卫生研究院文献>Contemporary Oncology >Two drugs are better than one. A short history of combined therapy of ovarian cancer
【2h】

Two drugs are better than one. A short history of combined therapy of ovarian cancer

机译:两种药物胜过一种药物。卵巢癌联合治疗的简短历史

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Combined therapy of ovarian cancer has a long history. It has been applied for many years. The first drug which was commonly combined with other chemotherapeutics was cisplatin. It turned out to be effective given together with alkylating agents as well as with taxanes. Another drug which is often the basis of first-line therapy is doxorubicin.The use of traditional chemotherapy is often limited due to side effects. This is why new drugs, targeted specifically at cancer cells (e.g. monoclonal antibodies or epidermal growth factor receptor inhibitors), offer a welcome addition when used in combination with conventional anticancer agents. Drugs applied in combination should be synergistic or at least additive. To evaluate the type of interaction between drugs in a plausible sequence, isobolographic analysis is used. This method allows one to assess whether the two agents could make an efficient combination, which might improve the therapy of ovarian cancer.
机译:卵巢癌联合疗法历史悠久。它已经应用了很多年。通常与其他化学疗法结合的第一种药物是顺铂。事实证明与烷基化剂以及紫杉烷类一起服用是有效的。经常作为一线治疗基础的另一种药物是阿霉素。由于副作用,传统化学疗法的使用常常受到限制。这就是为什么专门针对癌细胞的新药物(例如单克隆抗体或表皮生长因子受体抑制剂)在与常规抗癌药联合使用时提供令人欢迎的添加物的原因。组合使用的药物应具有协同作用或至少是添加剂。为了评估药物之间可能发生的相互作用的类型,使用了等效线描图法分析。这种方法可以评估两种药物是否可以有效组合,从而改善卵巢癌的治疗。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号